Valneva SE (NASDAQ:VALN) Sees Significant Increase in Short Interest

Valneva SE (NASDAQ:VALN) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 16,900 shares, a growth of 191.4% from the February 28th total of 5,800 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average trading volume of 57,400 shares, the short-interest ratio is presently 0.3 days.

Valneva Stock Up 1.3 %

Shares of NASDAQ:VALN opened at $7.25 on Friday. The company’s fifty day moving average is $6.57 and its 200-day moving average is $5.61. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50. The company has a market capitalization of $589.14 million, a PE ratio of -55.77 and a beta of 1.93.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.32). The firm had revenue of $56.48 million during the quarter, compared to analyst estimates of $55.64 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%. Equities research analysts predict that Valneva will post 0.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Guggenheim lowered their target price on shares of Valneva from $17.00 to $15.00 and set a “buy” rating on the stock in a research note on Monday. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Valneva in a research note on Friday, March 21st.

Hedge Funds Weigh In On Valneva

An institutional investor recently bought a new position in Valneva stock. ABC Arbitrage SA bought a new stake in Valneva SE (NASDAQ:VALN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 19,244 shares of the company’s stock, valued at approximately $84,000. Hedge funds and other institutional investors own 11.39% of the company’s stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.